Introduction to the Issue

- In most European countries, medical devices have not been subject to HTA as often as pharmaceuticals.
- They have, however, been subject to procurement practices within health care systems.
- Assessment of value should be an important feature of both HTA and procurement practices.
- The relative lack of clinical evidence and the incremental nature of innovation poses challenges for value assessment for medical devices.
- Proposed developments in HTA within the EU and efforts to improve procurement practices suggest that the paradigm is changing for the value assessment of medical devices.
Topics for Discussion

• Which methodologies and innovative approaches are emerging in assessing the value of medical devices?
• What are the expectations of different stakeholders?
• What are the practical challenges and the potential solutions?

Our Panelists

• Øyvind Melien, MD,PhD Director of Reviews and HTA, Norwegian Institute of Public Health, Oslo, Norway
• Rabia Kahveci, MD,MSc, Associate Professor and Director of ANHTA, Ankara, Turkey
• Yves Verboven, Director of Market Access and Economic Policies, MedTech Europe, Brussels, Belgium